Astrana Health (NASDAQ:ASTH) Rating Increased to Hold at Macquarie

Astrana Health (NASDAQ:ASTH) was upgraded by investment analysts at Macquarie to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on ASTH. KeyCorp assumed coverage on Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. BTIG Research raised their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Robert W. Baird upped their price target on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They issued a “buy” rating and a $66.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.17.

Astrana Health Stock Down 3.5 %

ASTH opened at $35.52 on Monday. Astrana Health has a twelve month low of $34.11 and a twelve month high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The business has a 50 day moving average price of $49.04 and a 200 day moving average price of $48.12. The firm has a market cap of $2.00 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. During the same period in the previous year, the company earned $0.47 earnings per share. Research analysts forecast that Astrana Health will post 1.16 EPS for the current year.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ASTH. Janus Henderson Group PLC bought a new position in Astrana Health in the third quarter valued at approximately $1,164,000. Royce & Associates LP acquired a new position in shares of Astrana Health during the 3rd quarter worth about $6,661,000. Amalgamated Bank bought a new stake in shares of Astrana Health in the 3rd quarter valued at about $713,000. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health in the 3rd quarter valued at approximately $13,383,000. Finally, Diamond Hill Capital Management Inc. bought a new position in Astrana Health during the 3rd quarter worth approximately $8,245,000. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.